Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine vs OROS-methylphenidate for emotional dysregulation in children with ADHD
ChiCTR2200062905Phase 4Recruiting
- Sponsor
- Peking University Sixth Hospital
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in attention deficit hyperactivity disorder (ADHD) comparing Atomoxetine with OROS-methylphenidate (2 arms). Primary endpoint: Emotion dysregulation symptom. Started Jan 2022; status: recruiting.
02
Drugs
atomoxetinemethylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on ChiCTR2200062905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062905.